PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at PhaseBio Pharmaceuticals, Inc..
PhaseBio Pharmaceuticals, Inc. is a company.
Key people at PhaseBio Pharmaceuticals, Inc..
Key people at PhaseBio Pharmaceuticals, Inc..
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for cardiovascular and cardiopulmonary diseases.[1][2][4] Its lead product candidate, bentracimab (PB2452), is a reversal agent for the antiplatelet drug ticagrelor, used to treat patients with acute coronary syndrome (ACS) or prior heart attacks by preventing blood clots; the company also advances PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension, and leverages elastin-like polypeptide (ELP) biopolymer technology for additional candidates.[1][2] With about 60 employees and headquarters in Malvern, Pennsylvania, PhaseBio has raised $389.2 million in funding, including a $120 million round, while reporting modest revenues peaking at $10.83 million in 2021.[1][2]
The company serves patients with high unmet needs in cardiovascular care, addressing problems like bleeding risks from antiplatelet therapies and resistant hypertension through therapies enabling less-frequent dosing and improved pharmacokinetics.[1][2][4] Growth momentum includes advancing bentracimab toward commercialization and expanding its ELP platform, though as a clinical-stage firm, it remains pre-revenue dominant with a focus on pivotal trials.[1][2]
PhaseBio emerged from expertise in biopolymer technology to tackle cardiovascular challenges, with CEO Jonathan Mow leading since 2014, bringing deep industry experience.[1][4] The company built on its proprietary ELP technology platform, initially applied to candidates like PB1046 (a once-weekly treatment for pulmonary arterial hypertension), evolving to prioritize bentracimab and PB6440 amid rising cardiovascular disease burdens—over 600,000 U.S. deaths annually.[1][2][4][5]
Early traction came through multiple funding rounds totaling $389.2 million, supporting clinical progression, with pivotal moments including bentracimab's development as a ticagrelor reversal agent and ELP's validation for protein/peptide therapies.[2] Key executives like CFO Lawrence Perkins (since 2022) and CTOs John Lee and Susan Arnold have driven R&D, humanizing PhaseBio's push from preclinical innovation to clinical-stage promise.[1]
PhaseBio rides the wave of precision cardiovascular therapies, addressing a market where cardiovascular disease claims one in four U.S. deaths—more than all cancers combined—and demands innovative reversal agents and hypertension treatments amid aging populations.[4][5] Timing aligns with surging demand for antiplatelet reversal amid ticagrelor's widespread ACS use, plus tailwinds from biopharma's shift to biopolymers for durable drug delivery.[1][2]
Market forces like rising chronic disease prevalence and funding for clinical-stage biotechs ($389.2M raised) favor PhaseBio, influencing the ecosystem by validating ELP tech for cardiopulmonary applications and potentially accelerating similar platforms.[2][5]
PhaseBio's path hinges on bentracimab's regulatory milestones, with commercialization potential unlocking revenues beyond current modest sales (e.g., $10.83M in 2021), alongside PB6440 Phase 1/2 data and ELP expansions.[1][2] Trends like AI-driven drug design and personalized cardio meds will shape progress, potentially amplifying influence if partnerships emerge.
As cardiovascular needs grow unabated, PhaseBio's innovative reversal agents and biopolymers position it to deliver outsized impact, fulfilling its mission to counter a disease affecting one in four.[4][5]
